Trove Therapeutics is a privately held, clinical-stage biopharmaceutical company based in Rockville, MD. They are focused on developing Therabron, a novel therapeutic protein, to address neglected and undertreated respiratory conditions. Their proprietary preparation of recombinant human SCGB1A1 protein, Therabron, has potential clinical applications in several respiratory diseases, aiming to impact the underlying disease process and resolve inflamed airways.
With specialized expertise in the creation, development, and commercialization of Therabron, Trove Therapeutics is led by experienced biopharmaceutical executives and professionals. They aim to replace native SCGB1A1 protein with the synthetic version Therabron to potentially benefit a range of respiratory conditions characterized by inflammation and native SCGB1A1 deficiency, including chronic sinusitis, bronchiolitis obliterans, and acute lung injury.
Generated from the website